XML 29 R11.htm IDEA: XBRL DOCUMENT
v3.23.1

Licensed rights and other intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract] |
Licensed rights and other intangible assets |
5. | Licensed rights and other intangible assets
The following provides information about our license rights and other intangible assets, net (in thousands):
|  | As of December 31, 2022 |  |  | As of December 31, 2021 |
|  | Gross |  |  |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
Intangible assets subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hormone therapy drug patents |  | $ | 6,225 |  |  | $ | 1,598 |  |  | $ | 4,627 |  |  | $ | 5,834 |  |  | $ | 1,042 |  |  | $ | 4,792 |
Hormone therapy drug patents applied and pending approval |  |  | 1,995 |  |  |  | — |  |  |  | 1,995 |  |  |  | 2,020 |  |  |  | — |  |  |  | 2,020 |
Intangible assets subject to amortization |  |  | 8,220 |  |  |  | 1,598 |  |  |  | 6,622 |  |  |  | 7,854 |  |  |  | 1,042 |  |  |  | 6,812 |
Intangible assets not subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks/trade name rights |  |  | 321 |  |  |  | — |  |  |  | 321 |  |  |  | 332 |  |  |  | — |  |  |  | 332 |
Intangible assets, net |  | $ | 8,541 |  |  | $ | 1,598 |  |  | $ | 6,943 |  |  | $ | 8,186 |  |  | $ | 1,042 |  |  | $ | 7,144 |
We recorded, in continuing operations, amortization expense related to patents of $0.6 million for 2022 and $0.3 million for 2021.We recorded amortization expense related to the exclusive license rights agreement with Population Council of $3.0 million for 2022 and 2021, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December 2022, which are excluded from the table above. Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):
Year ending December 31, |
2023 |  | $ | 337 |
2024 |  |  | 439 |
2025 |  |  | 438 |
2026 |  |  | 438 |
2027 |  |  | 438 |
Thereafter |  |  | 2,537 |
Total |  | $ | 4,627 |
We use a combination of qualitative and quantitative factors to assess licensed rights and intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of December 31, 2022 or 2021, therefore, no write downs were recorded to our licensed rights and other intangible assets.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -URI https://asc.fasb.org/subtopic&trid=2144471 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration